CY1112826T1 - [4-(6-αλογονο-7-υποκατεστημενες-2,4-διοξο-1,4-διϋδρο-2η-κιναζολιν-3-υλ)-φαινυλ]-5-χλωρο-θειοφαιν-2-υλ-σουλφονυλουριες και μορφες και μεθοδοι που σχετιζονται με αυτες - Google Patents
[4-(6-αλογονο-7-υποκατεστημενες-2,4-διοξο-1,4-διϋδρο-2η-κιναζολιν-3-υλ)-φαινυλ]-5-χλωρο-θειοφαιν-2-υλ-σουλφονυλουριες και μορφες και μεθοδοι που σχετιζονται με αυτεςInfo
- Publication number
- CY1112826T1 CY1112826T1 CY20121100393T CY121100393T CY1112826T1 CY 1112826 T1 CY1112826 T1 CY 1112826T1 CY 20121100393 T CY20121100393 T CY 20121100393T CY 121100393 T CY121100393 T CY 121100393T CY 1112826 T1 CY1112826 T1 CY 1112826T1
- Authority
- CY
- Cyprus
- Prior art keywords
- forms
- thrombosis
- sulfuryl
- quinazoline
- dioxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει νέες ενώσεις σουλφονυλουρίας του τύπου (Ι) και φαρμακευτικώς αποδεκτά παράγωγα και πολύμορφες και άμορφες μορφές αυτών. Οι ενώσεις στις διάφορες μορφές τους είναι αποτελεσματικοί αναστολείς υποδοχέα ΑDΡ αιμοπεταλίων και μπορεί να χρησιμοποιούνται σε διάφορες φαρμακευτικές συνθέσεις, και είναι ιδιαιτέρως αποτελεσματικές για την πρόληψη ή/και θεραπευτική αγωγή καρδιαγγειακών ασθενειών, ιδιαιτέρως εκείνων των ασθενειών που σχετίζονται με τη θρόμβωση. Η εφεύρεση παρέχει επίσης μια μέθοδο για την παρασκευή τέτοιων ενώσεων και μορφών και για την πρόληψη ή θεραπευτική αγωγή θρόμβωσης και σχετιζόμενων με τη θρόμβωση καταστάσεων σε ένα θηλαστικό, η οποία περιλαμβάνει το στάδιο χορήγησης μιας θεραπευτικώς αποτελεσματικής ποσότητας μιας ένωσης του τύπου (Ι) ή ενός φαρμακευτικώς αποδεκτού άλατος ή μορφές αυτού.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73365005P | 2005-11-03 | 2005-11-03 | |
EP06827506A EP1951254B1 (en) | 2005-11-03 | 2006-11-03 | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1112826T1 true CY1112826T1 (el) | 2016-02-10 |
Family
ID=38023842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100393T CY1112826T1 (el) | 2005-11-03 | 2012-04-04 | [4-(6-αλογονο-7-υποκατεστημενες-2,4-διοξο-1,4-διϋδρο-2η-κιναζολιν-3-υλ)-φαινυλ]-5-χλωρο-θειοφαιν-2-υλ-σουλφονυλουριες και μορφες και μεθοδοι που σχετιζονται με αυτες |
Country Status (21)
Country | Link |
---|---|
US (3) | US20070208045A1 (el) |
EP (2) | EP1951254B1 (el) |
JP (1) | JP5509406B2 (el) |
KR (1) | KR101423483B1 (el) |
CN (1) | CN101300013B (el) |
AR (1) | AR056762A1 (el) |
AT (1) | ATE540034T1 (el) |
AU (1) | AU2006311795B2 (el) |
BR (1) | BRPI0618210A2 (el) |
CA (1) | CA2627719C (el) |
CY (1) | CY1112826T1 (el) |
DK (1) | DK1951254T3 (el) |
EA (1) | EA017402B1 (el) |
ES (1) | ES2380814T3 (el) |
HK (1) | HK1121051A1 (el) |
IL (1) | IL191193A (el) |
NZ (2) | NZ567747A (el) |
PT (1) | PT1951254E (el) |
TW (2) | TW200728260A (el) |
WO (2) | WO2007056167A2 (el) |
ZA (1) | ZA200804241B (el) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5020073B2 (ja) | 2004-06-18 | 2012-09-05 | ミレニアム ファーマシューティカルズ インク. | 第Xa因子阻害剤 |
AU2006311795B2 (en) * | 2005-11-03 | 2013-01-17 | Portola Pharmaceuticals, Inc. | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto |
TW200813017A (en) | 2006-05-05 | 2008-03-16 | Millennium Pharm Inc | Factor XA inhibitors |
JPWO2008133155A1 (ja) | 2007-04-19 | 2010-07-22 | アステラス製薬株式会社 | 二環式ヘテロ環化合物 |
US20090156620A1 (en) * | 2007-05-02 | 2009-06-18 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
EP2076510A2 (en) * | 2007-05-02 | 2009-07-08 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof, and formulations thereof, for the treatment of thrombosis and trombosis related conditions |
EP2146705B1 (en) * | 2007-05-02 | 2014-03-05 | Portola Pharmaceuticals, Inc. | Combination therapy with a compound acting as a platelet adp receptor inhibitor |
CN101795682A (zh) | 2007-05-02 | 2010-08-04 | 波托拉医药品公司 | 直接起效和可逆的p2y12抑制剂的静脉内和口服给药 |
MX2009013431A (es) * | 2007-06-18 | 2010-01-15 | Sanofi Aventis | Derivados de pirrol como antagonistas de p2y12. |
CN101654441B (zh) * | 2008-08-19 | 2012-10-03 | 信谊药厂 | 抗凝化合物、组合物及其用途 |
JP2012508773A (ja) * | 2008-11-14 | 2012-04-12 | ポートラ ファーマシューティカルズ, インコーポレイテッド | 低いpHでの難水溶性のイオン化活性薬剤の制御放出のための固体組成物およびその使用方法 |
WO2011006169A1 (en) | 2009-07-10 | 2011-01-13 | Portola Pharmaceuticals, Inc. | Methods for diagnosis and treatment of thrombotic disorders mediated by cyp2c19*2 |
JP5597202B2 (ja) | 2009-08-28 | 2014-10-01 | 第一三共株式会社 | 3−(ビアリールオキシ)プロピオン酸誘導体 |
EP2513094B1 (en) | 2009-12-17 | 2015-12-16 | Millennium Pharmaceuticals, Inc. | Crystalline salts of a factor xa inhibitor |
US8742120B2 (en) | 2009-12-17 | 2014-06-03 | Millennium Pharmaceuticals, Inc. | Methods of preparing factor xa inhibitors and salts thereof |
WO2011088152A1 (en) | 2010-01-12 | 2011-07-21 | Portola Pharmaceuticals, Inc. | Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof |
WO2011137459A1 (en) | 2010-04-30 | 2011-11-03 | Portola Pharmaceuticals, Inc. | Dosage forms of elinogrel and methods of injectable administration thereof |
WO2012072824A1 (en) * | 2010-12-03 | 2012-06-07 | Novartis Ag | Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof |
WO2014042176A1 (ja) * | 2012-09-14 | 2014-03-20 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の製造方法およびその製造中間体 |
RU2556198C1 (ru) * | 2014-04-10 | 2015-07-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук | Способ профилактики развития постперикардиотомного синдрома у больных ишемической болезнью сердца, подвергшихся коронарному шунтированию |
WO2017003723A1 (en) | 2015-07-01 | 2017-01-05 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
EP3658560A4 (en) | 2017-07-25 | 2021-01-06 | Crinetics Pharmaceuticals, Inc. | SOMATOSTAT IN MODULATORS AND USES THEREOF |
WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE845042C (de) | 1950-07-14 | 1952-07-28 | Basf Ag | Verfahren zur Herstellung von Sulfonylurethanen, -harnstoffen oder -carbonsaeureamiden |
US3847925A (en) * | 1971-07-15 | 1974-11-12 | En Nom Collectif Science Et Ci | Benzenesulfonyl semicarbazides |
DE3134780A1 (de) * | 1981-09-02 | 1983-03-10 | Hoechst Ag, 6000 Frankfurt | "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung" |
US4720450A (en) * | 1985-06-03 | 1988-01-19 | Polaroid Corporation | Thermal imaging method |
GB9413975D0 (en) | 1994-07-11 | 1994-08-31 | Fujisawa Pharmaceutical Co | New heterobicyclic derivatives |
US5314902A (en) * | 1993-01-27 | 1994-05-24 | Monsanto Company | Urea derivatives useful as platelet aggregation inhibitors |
US6268380B1 (en) | 1993-02-19 | 2001-07-31 | G. D. Searle & Co. | Urea derivatives useful as platelet aggregation inhibitors |
US5614539A (en) | 1993-03-15 | 1997-03-25 | G. D. Searle & Co. | Urea compounds which are useful as platelet aggregation inhibitors |
TW448161B (en) | 1994-07-14 | 2001-08-01 | Otsuka Pharma Co Ltd | Cyclic amide derivatives |
JPH0881442A (ja) | 1994-07-14 | 1996-03-26 | Otsuka Pharmaceut Co Ltd | 環状アミド誘導体 |
US6413724B1 (en) * | 1996-10-28 | 2002-07-02 | Versicor, Inc. | Solid phase and combinatorial library syntheses of fused 2,4-pyrimidinediones |
US6160000A (en) * | 1996-12-23 | 2000-12-12 | Merck & Co., Inc. | Antidiabetic agents based on aryl and heteroarylacetic acids |
JPH10195323A (ja) | 1997-01-09 | 1998-07-28 | Nippon Paper Ind Co Ltd | 新規なスルホニルグアニジン化合物及びそれを用いた感熱記録体 |
SE9702774D0 (sv) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
EP1047699A1 (en) | 1998-01-15 | 2000-11-02 | Cor Therapeutics, Inc. | Platelet adp receptor inhibitors |
JP2000204081A (ja) | 1998-02-05 | 2000-07-25 | Takeda Chem Ind Ltd | スルホンアミド誘導体、その製造法及び用途 |
US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
DE60114994T2 (de) | 2000-02-04 | 2006-08-03 | Portola Pharmaceuticals, Inc., South San Francisco | Blutplättchen-adp-rezeptor-inhibitoren |
DE60144284D1 (de) * | 2000-11-01 | 2011-05-05 | Millennium Pharm Inc | Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung |
WO2003059288A2 (en) * | 2002-01-09 | 2003-07-24 | Enzrel, Inc. | Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds |
US20040242658A1 (en) * | 2003-01-08 | 2004-12-02 | Dr. Reddy's Laboratories Limited | Amorphous form of rosiglitazone maleate and process for preparation thereof |
DE602004024093D1 (de) * | 2003-10-03 | 2009-12-24 | Portola Pharm Inc | 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe |
AU2006311795B2 (en) | 2005-11-03 | 2013-01-17 | Portola Pharmaceuticals, Inc. | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto |
EP2076510A2 (en) * | 2007-05-02 | 2009-07-08 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof, and formulations thereof, for the treatment of thrombosis and trombosis related conditions |
CN101795682A (zh) * | 2007-05-02 | 2010-08-04 | 波托拉医药品公司 | 直接起效和可逆的p2y12抑制剂的静脉内和口服给药 |
US20090156620A1 (en) * | 2007-05-02 | 2009-06-18 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
-
2006
- 2006-11-03 AU AU2006311795A patent/AU2006311795B2/en not_active Ceased
- 2006-11-03 DK DK06827506.4T patent/DK1951254T3/da active
- 2006-11-03 BR BRPI0618210-0A patent/BRPI0618210A2/pt not_active Application Discontinuation
- 2006-11-03 WO PCT/US2006/042998 patent/WO2007056167A2/en active Application Filing
- 2006-11-03 AR ARP060104840A patent/AR056762A1/es unknown
- 2006-11-03 TW TW095140749A patent/TW200728260A/zh unknown
- 2006-11-03 CN CN2006800410635A patent/CN101300013B/zh not_active Expired - Fee Related
- 2006-11-03 US US11/556,518 patent/US20070208045A1/en not_active Abandoned
- 2006-11-03 CA CA2627719A patent/CA2627719C/en not_active Expired - Fee Related
- 2006-11-03 EP EP06827506A patent/EP1951254B1/en active Active
- 2006-11-03 AT AT06827506T patent/ATE540034T1/de active
- 2006-11-03 US US11/556,490 patent/US8058284B2/en active Active
- 2006-11-03 PT PT06827506T patent/PT1951254E/pt unknown
- 2006-11-03 EP EP11176014A patent/EP2428514A1/en not_active Withdrawn
- 2006-11-03 WO PCT/US2006/043093 patent/WO2007056219A2/en active Application Filing
- 2006-11-03 TW TW095140753A patent/TWI397529B/zh not_active IP Right Cessation
- 2006-11-03 JP JP2008539089A patent/JP5509406B2/ja active Active
- 2006-11-03 ES ES06827506T patent/ES2380814T3/es active Active
- 2006-11-03 EA EA200801245A patent/EA017402B1/ru not_active IP Right Cessation
- 2006-11-03 KR KR1020087013178A patent/KR101423483B1/ko active IP Right Grant
- 2006-11-03 NZ NZ567747A patent/NZ567747A/en not_active IP Right Cessation
- 2006-11-03 NZ NZ596025A patent/NZ596025A/xx not_active IP Right Cessation
- 2006-11-03 ZA ZA200804241A patent/ZA200804241B/xx unknown
-
2008
- 2008-05-01 IL IL191193A patent/IL191193A/en not_active IP Right Cessation
-
2009
- 2009-01-13 HK HK09100322.0A patent/HK1121051A1/xx not_active IP Right Cessation
-
2011
- 2011-10-11 US US13/271,037 patent/US20120088736A1/en not_active Abandoned
-
2012
- 2012-04-04 CY CY20121100393T patent/CY1112826T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1112826T1 (el) | [4-(6-αλογονο-7-υποκατεστημενες-2,4-διοξο-1,4-διϋδρο-2η-κιναζολιν-3-υλ)-φαινυλ]-5-χλωρο-θειοφαιν-2-υλ-σουλφονυλουριες και μορφες και μεθοδοι που σχετιζονται με αυτες | |
DE60114994D1 (de) | Blutplättchen-adp-rezeptor-inhibitoren | |
CY1118128T1 (el) | Αρυλ διϋδροπυριδινονες και πιπεριδiνονες ως αναστολεις του mgat2 | |
NO20072371L (no) | Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister | |
CY1112024T1 (el) | Αναστολεις υποδοχεων adp αιμοπεταλιων | |
CY1115533T1 (el) | Παραγωγα χολικου οξεος ως προσδετες fxr για την προληψη ή τη θεραπευτικη αγωγη νοσηματων ή καταστασεων οι οποιες προκαλουνται με τη μεσολαβηση fxr | |
NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
ATE517882T1 (de) | Chinolinderivate | |
EA200870117A1 (ru) | Азаиндоловые ингибиторы аурора-киназ | |
CY1110977T1 (el) | Υποκατεστημενα παραγωγα ινδολης για φαρμακευτικη συνθεση για θεραπεια ασθενειων του αναπνευστικου | |
CY1123426T1 (el) | Μεθοδος για τη ληψη κρυσταλλων αλατος μεγλουμινης του 1-(5,6-διχλωρο-1η-βενζο[d]ιμιδαζολ-2-υλο)-1η-πυραζολο-4-καρβοξυλικου οξεος | |
CY1113324T1 (el) | Υποκατεστημενα αμιδικα παραγωγα ως αναστολεις πρωτεϊνικων κινασων | |
NO20063748L (no) | Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer | |
CY1110583T1 (el) | Παραγωγα ν4-φαινυλ-κιναζολινο-4-αμινης και σχετικες ενωσεις ως αναστολεις υποδοχεα κινασης τυροσινης τυπου i erbb για τη θεραπεια υπερπολλαπλασιαστικων ασθενειων | |
CY1109227T1 (el) | Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων | |
CY1109860T1 (el) | Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις | |
EA200500814A1 (ru) | Производные пирролопиримидина | |
SE0400284D0 (sv) | Novel compounds | |
ECSP034744A (es) | Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos | |
CY1112366T1 (el) | Ενωσεις βενζιμιδαζολης- καρβοξαμιδης ως αγωνιστες του 5-ητ4 υποδοχεα | |
CY1106679T1 (el) | Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα | |
NO20070453L (no) | Kondenserte heterocykliske kinase inhibitorer | |
CY1107426T1 (el) | Νεα παραγωγα φθοριογλυκοσιδιων απο πυραζολες, φαρμακευτικα προϊοντα που περιεχουν τις εν λογω ενωσεις και η χρηση αυτων | |
EA201270546A1 (ru) | ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ | |
NO20064065L (no) | Diaminopyrimidiner som P2X3 og P2X2/3 antagonister |